These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 15220416

  • 1. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J, Stevens M, Van Rompay AR, Bird LE, Ren J, De Clercq E, Oberg B, Stammers DK, Karlsson A, Balzarini J.
    J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
    [Abstract] [Full Text] [Related]

  • 2. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H, Aertsen A, Van Laethem K, Vandamme AM, De Clercq E, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ, Balzarini J.
    Virology; 2001 Feb 01; 280(1):97-106. PubMed ID: 11162823
    [Abstract] [Full Text] [Related]

  • 3. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN.
    J Virol; 2004 Dec 01; 78(24):13553-61. PubMed ID: 15564466
    [Abstract] [Full Text] [Related]

  • 4. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.
    Antimicrob Agents Chemother; 2006 Aug 01; 50(8):2772-81. PubMed ID: 16870771
    [Abstract] [Full Text] [Related]

  • 5. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.
    Venkatachalam TK, Mao C, Uckun FM.
    Biochem Pharmacol; 2004 May 15; 67(10):1933-46. PubMed ID: 15130770
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M, Golebiewski WM, Graham L, Turpin JA, Rice WG, Fliakas-Boltz V, Buckheit RW.
    J Med Chem; 1996 Aug 02; 39(16):3217-27. PubMed ID: 8759644
    [Abstract] [Full Text] [Related]

  • 8. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.
    Antiviral Res; 2006 Jun 02; 70(2):66-74. PubMed ID: 16472877
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W.
    Antivir Ther; 2004 Feb 02; 9(1):57-65. PubMed ID: 15040537
    [Abstract] [Full Text] [Related]

  • 14. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB, Buckheit RW, Gulakowski RJ, Currens MJ, Vistica DT, Shoemaker RH, Stinson SF, Russell JD, Bader JP, Narayanan VL, Schultz RJ, Brouwer WG, Felauer EE, Boyd MR.
    J Pharmacol Exp Ther; 1996 Jan 02; 276(1):298-305. PubMed ID: 8558446
    [Abstract] [Full Text] [Related]

  • 15. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E.
    J Mol Biol; 1994 Oct 28; 243(3):369-87. PubMed ID: 7525966
    [Abstract] [Full Text] [Related]

  • 16. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J, Tamalet C.
    J Med Virol; 2005 Mar 28; 75(3):381-90. PubMed ID: 15648062
    [Abstract] [Full Text] [Related]

  • 17. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
    J Med Chem; 2005 Nov 17; 48(23):7153-65. PubMed ID: 16279773
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2004 Jan 17; 65(1):244-51. PubMed ID: 14722257
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L, Betancor G, Matamoros T.
    Antiviral Res; 2011 Nov 17; 92(2):139-49. PubMed ID: 21896288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.